SIFI is affiliated with the European Commission for AKANTIOR®

AKANTIOR® (Polihexanid) is the first and only drug for the treatment of Acanthamoeba–Keratitis

CATANIA, Italy, 26. August 2024 /PRNewswire/ — SIFI, a global healthcare company, has awarded the European Commission AKANTIOR® (Polihexanid) for the treatment of Acanthamoeba Keratitis (AK) in adults and children for 12 years the orphan status of best-in-class products. AKANTIOR is the first and only in Europe-approved therapy for humans, leading to AK.

AK is a very good choice, heavy, sharp and the Sehpower deceiving Hornhead infection, which is characterized by the strong Schmerzen and Photophobia. AK would be sold by a free Amöbe, the Acanthamöbe, and involved for all contacts.

“This current approval is a significant step towards a new global treatment standard for patients with AK and marks 15 years of research and development,” says Fabrizio Chines, Chairman and CEO from SIFI. “For the first time, AK patients in Europe are offered a unique treatment therapy that introduces a new approach to the treatment of this disease that can lead to blindness. AKANTIOR is the first and only drug for AK, and our team is the best, polihexanide for other infectious diseases with pilkeratitis at the EMA, for the EMA and the FDA for orphan drug status.

“AKANTIOR is available as monotherapy with the treatment protocol of medical medicine of 86% and is in the best way, the standard treatment for this severe and weak disease”, explained Professor John Arrow from Moorfields Eye Hospital and the UCL Institute of Ophthalmology, of the phase III ODAK trial. After 15 years of research and investigation during SIFI, which were carried out in the separate clinical phase III study, polihexanide 0.08% has now been approved by the European Medicines Agency and the European Commission as the first treatment for Acanthamoeben-Keratitis-zugelassen. This breakthrough could lead to the results of the treatment and the potential possibilities being affected, blindness is caused and increased. If a treatment with a therapeutic treatment is carried out with the details of the treatment protocol, it is used in the phase 3 study. Because the notivity of the variable, individual treatment, the time for the world used by the patient, and it is an effective, standardized standardization of care, the of every clinician could be, would be one of those things that could never happen in the study. also in the current Compassionate Use Program outside the stricter study number.”

“With the approval of AKANTIOR, AK patients (or AK warriors) have now come a step closer to the best possible treatment in the EU. This Meilenstein is an important writer on the way to a fair insurance for all AK warriors and gives a courtesy to a better future”, commented Juliette Vila Sinclair Spencea treatment of patients with selected diseases, care and gründerin of AK Eye Foundation – of the first global foundation, which has the Krankheit-widmet.

In Europe, SIFI is planning the first commercial market launch in Germany in the last few quarters, following the new markets based on the local regulatory, health, technical, business and regulatory processes, in a general way in France, Italy, Rumänien, Spanien, Großbritannien and der Türkei with a German approach. 430 million. People, in general, have a positive relationship with partners, in other European countries with a population of 180 million. People. Removal of removal symptoms during the serious disease keratitis on one of four patients for a million einwohners.

INFORMATION FOR AKANTIOR®: AKANTIOR (Polihexanid 0.08%) is the best treatment for the treatment of Acanthamoeba keratitis. There is an anti-amöbic polymer that is in the trophozoites when the zysts of the protozoa-acanthamoeba act. There is a dose of 0.8 mg/ml (0.08%), the treatment as monotherapy-augentropfen in a dose treatment is very light. The European Commission confirms the orphan status of products. The FDA has granted SIFI the orphan drug status for the treatment of acanthamoeba keratitis.

Information about Acanthamoeba Keratitis (AK): AK is one of the most used selenium, acute, severe parasitic hornhead infection, which is caused by Acanthamöben, a free amoeba. The incidence of AK has become rapid in recent years. It is a good idea to perform urgent treatment, one of the reasons for doing so. If you want to undergo treatment, you can go blind or undergo more horn transplants and perform a higher transplant. If you try people with all alternative groups, most people can contact other people or less. The messages from patients are unnoticed and extremely light and can now no longer or lead a normal life, but the symptoms disappear.

INFORMATION FOR SIFI: SIFI is an international university of medical science with headquarters in Italy, it is an integrated business model that does research and development with its recovery and marketing that extends into the pharmaceutical sector as well as the biomedical sector. See our Gründung in the year 1935 year Our soul, the life of men through meaningful innovations in human health is improved. SIFI exports in more than 40 Länder Weltweit and is directly in the most important European markets, in Mexico and über Joint Ventures in China and the United Arab Emirates. For more information, please visit www.sifigroup.com.

View original content:https://www.prnewswire.com/news-releases/sifi-erhalt-die-zulassung-der-europaischen-kommission-fur-akantior-302229449.html